Log out Go to App
Go to App

Learning Materials

Features

Discover

Chapter 41: Problem 18

Nucleoside analogue reverse transcriptase inhibitors are drugs of diverse chemical structure that act by non-competitive inhibition of HIV-1 reverse transcriptase. True/False

Short Answer

Expert verified
Answer: False

Step by step solution

01

Understanding Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)

Nucleoside analogue reverse transcriptase inhibitors (NRTIs) are a class of antiretroviral medications used to treat HIV infection by blocking the action of reverse transcriptase, an enzyme required by the virus for replication. NRTIs resemble natural nucleosides, the building blocks of DNA, and are able to effectively compete with them for incorporation into the growing viral DNA chain.
02

Mechanism of NRTIs

When an NRTI is incorporated into the viral DNA chain, it lacks the necessary 3'-hydroxyl group required for the addition of the next nucleotide. This causes premature termination of the DNA synthesis, preventing further replication of the virus.
03

Competitive versus non-competitive inhibition

Inhibition can be classified as competitive, non-competitive, or uncompetitive. In competitive inhibition, the inhibitor and substrate compete for the same active site on the enzyme, and inhibition can be reduced or reversed by increasing the concentration of the substrate. Whereas, in non-competitive inhibition, the inhibitor binds to an allosteric site on the enzyme other than the active site, causing a change in enzyme conformation and decreased enzymatic activity regardless of substrate concentration.
04

Analyzing the statement

The statement claims that NRTIs are "non-competitive inhibitors" of HIV-1 reverse transcriptase. As we've seen in the explanation of their mechanism, NRTIs act by incorporating themselves into the growing viral DNA chain, competing with natural nucleotides for incorporation. This indicates their mode of action to be competitive, not non-competitive.
05

Determining the answer

Based on our understanding of NRTIs and their mechanism of action as competitive inhibitors of HIV-1 reverse transcriptase, we can conclude that the statement is False.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Start your free trial

Over 30 million students worldwide already upgrade their learning with Vaia!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

Which of the following protease inhibitors is the most powerful inhibitor of the \(\mathbf{P 4 5 0}\) enzyme? a. Atazanavir b. Fosamprenavir c. Indinavir d. Nelfinavir e. Ritonavir

What is correct about the "Trojan Horse" model of HIV invasion into the CNS? a. Proposes that monocyte-macrophage carry progeny virions from blood to the brain inside cytoplasmic vacuoles and across the blood-brain barrier b. Requires an inflammatory response in the brain, which elicits a chemokine gradient c. After infiltrating the brain parenchyma, blood borne monocyte-macrophages also release additional chemokines and further attract additional inflammatory cells d. Does not require productive viral replication in brain microvascular endothelial cells e. All of the above

Which of the following combinations will not be recommended for first line therapy in a patient with HIV associated dementia? a. Zidovudine plus lamivudine plus efavirenz b. Tenofovir plus emtricitabine plus lopinavir/ritonavir c. Tenofovir plus emtricitabine plus atazanavir/ritonavir d. Lamivudine plus abacavir plus fosamprenavir e. Zidovudine plus lamivudine plus abacavir

Which of the following class of drugs is not recommended for first line therapy in patients with HIVassociated dementia? a. Nucleoside reverse transcriptase inhibitors b. Non-nucleoside reverse transcriptase inhibitors c. Protease inhibitors d. Entry inhibitors e. All can be used as first line agents in the treatment of HAD

Recent guidelines for starting anti-retroviral therapy recommend that patients with advanced disease, as manifested by the development of an AIDS-defining illness including HAD, or presence of severe symptoms such as unexplained fever, persistent diarrhea, or unexplained weight loss, should be started on ART if their \(\mathrm{CD}^{*} \mathrm{~T}\) cell count is \(<\mathbf{1 0 0}\). True/False
See all solutions

Recommended explanations on Biology Textbooks

Ecosystems

Read Explanation

Biology Experiments

Read Explanation

Cell Communication

Read Explanation

Microbiology

Read Explanation

Control of Gene Expression

Read Explanation

Heredity

Read Explanation
View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free